S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NYSE:NVTA

Invitae Competitors

$40.13
+0.33 (+0.83 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$37.70
Now: $40.13
$41.07
50-Day Range
$39.80
MA: $50.46
$56.93
52-Week Range
$7.41
Now: $40.13
$61.59
Volume4.85 million shs
Average Volume4.26 million shs
Market Capitalization$7.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Competitors

Invitae (NYSE:NVTA) Vs. LH, DGX, GH, NTRA, CDNA, and VCYT

Should you be buying NVTA stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Invitae, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT).

Laboratory Co. of America (NYSE:LH) and Invitae (NYSE:NVTA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Laboratory Co. of America and Invitae, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
Invitae04302.43

Laboratory Co. of America presently has a consensus price target of $235.4667, indicating a potential downside of 1.85%. Invitae has a consensus price target of $45.1429, indicating a potential upside of 12.49%. Given Invitae's higher possible upside, analysts plainly believe Invitae is more favorable than Laboratory Co. of America.

Risk and Volatility

Laboratory Co. of America has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Invitae has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500.

Insider and Institutional Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 78.6% of Invitae shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 2.9% of Invitae shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Laboratory Co. of America and Invitae's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
Invitae-183.50%-81.19%-37.28%

Earnings and Valuation

This table compares Laboratory Co. of America and Invitae's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.02$823.80 million$11.3221.19
Invitae$216.82 million32.70$-241,960,000.00($2.28)-17.60

Laboratory Co. of America has higher revenue and earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

Summary

Laboratory Co. of America beats Invitae on 10 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and Invitae (NYSE:NVTA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Quest Diagnostics and Invitae's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Invitae-183.50%-81.19%-37.28%

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 78.6% of Invitae shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Comparatively, 2.9% of Invitae shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Quest Diagnostics and Invitae's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
Invitae$216.82 million32.70$-241,960,000.00($2.28)-17.60

Quest Diagnostics has higher revenue and earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Quest Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Invitae has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Quest Diagnostics and Invitae, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
Invitae04302.43

Quest Diagnostics currently has a consensus price target of $129.00, indicating a potential upside of 11.60%. Invitae has a consensus price target of $45.1429, indicating a potential upside of 12.49%. Given Invitae's stronger consensus rating and higher possible upside, analysts plainly believe Invitae is more favorable than Quest Diagnostics.

Summary

Quest Diagnostics beats Invitae on 9 of the 14 factors compared between the two stocks.

Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Guardant Health and Invitae's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardant Health-67.14%-19.22%-16.37%
Invitae-183.50%-81.19%-37.28%

Insider and Institutional Ownership

84.9% of Guardant Health shares are held by institutional investors. Comparatively, 78.6% of Invitae shares are held by institutional investors. 13.0% of Guardant Health shares are held by company insiders. Comparatively, 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$214.38 million68.63$-75,650,000.00($0.84)-175.21
Invitae$216.82 million32.70$-241,960,000.00($2.28)-17.60

Guardant Health has higher earnings, but lower revenue than Invitae. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Guardant Health has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Invitae has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Guardant Health and Invitae, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardant Health00903.00
Invitae04302.43

Guardant Health currently has a consensus price target of $170.50, indicating a potential upside of 15.84%. Invitae has a consensus price target of $45.1429, indicating a potential upside of 12.49%. Given Guardant Health's stronger consensus rating and higher possible upside, equities analysts clearly believe Guardant Health is more favorable than Invitae.

Summary

Guardant Health beats Invitae on 11 of the 14 factors compared between the two stocks.

Natera (NASDAQ:NTRA) and Invitae (NYSE:NVTA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Natera and Invitae's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natera-52.11%-53.39%-25.89%
Invitae-183.50%-81.19%-37.28%

Insider and Institutional Ownership

94.9% of Natera shares are held by institutional investors. Comparatively, 78.6% of Invitae shares are held by institutional investors. 9.3% of Natera shares are held by company insiders. Comparatively, 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Natera and Invitae's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$302.33 million32.78$-124,830,000.00($1.99)-58.34
Invitae$216.82 million32.70$-241,960,000.00($2.28)-17.60

Natera has higher revenue and earnings than Invitae. Natera is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Natera has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Invitae has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Natera and Invitae, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natera011002.91
Invitae04302.43

Natera currently has a consensus price target of $102.1818, indicating a potential downside of 11.98%. Invitae has a consensus price target of $45.1429, indicating a potential upside of 12.49%. Given Invitae's higher possible upside, analysts clearly believe Invitae is more favorable than Natera.

Summary

Natera beats Invitae on 11 of the 14 factors compared between the two stocks.

CareDx (NASDAQ:CDNA) and Invitae (NYSE:NVTA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Insider and Institutional Ownership

78.6% of Invitae shares are held by institutional investors. 3.1% of CareDx shares are held by company insiders. Comparatively, 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CareDx and Invitae's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$127.07 million30.65$-21,970,000.00($0.52)-152.08
Invitae$216.82 million32.70$-241,960,000.00($2.28)-17.60

CareDx has higher earnings, but lower revenue than Invitae. CareDx is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for CareDx and Invitae, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CareDx01413.00
Invitae04302.43

CareDx currently has a consensus price target of $75.8333, indicating a potential downside of 4.11%. Invitae has a consensus price target of $45.1429, indicating a potential upside of 12.49%. Given Invitae's higher possible upside, analysts clearly believe Invitae is more favorable than CareDx.

Volatility and Risk

CareDx has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Invitae has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Profitability

This table compares CareDx and Invitae's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CareDx-11.79%-10.95%-7.94%
Invitae-183.50%-81.19%-37.28%

Summary

CareDx beats Invitae on 9 of the 15 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Insider and Institutional Ownership

78.6% of Invitae shares are held by institutional investors. 2.9% of Invitae shares are held by insiders. Comparatively, 8.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Invitae and Veracyte's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$216.82 million32.70$-241,960,000.00($2.28)-17.60
Veracyte$120.37 million32.32$-12,600,000.00($0.27)-215.04

Veracyte has lower revenue, but higher earnings than Invitae. Veracyte is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Invitae and Veracyte, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invitae04302.43
Veracyte11602.63

Invitae currently has a consensus target price of $45.1429, indicating a potential upside of 12.49%. Veracyte has a consensus target price of $59.2857, indicating a potential upside of 2.11%. Given Invitae's higher possible upside, research analysts plainly believe Invitae is more favorable than Veracyte.

Risk and Volatility

Invitae has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Profitability

This table compares Invitae and Veracyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invitae-183.50%-81.19%-37.28%
Veracyte-30.46%-12.27%-10.95%

Summary

Veracyte beats Invitae on 8 of the 14 factors compared between the two stocks.


Invitae Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$239.91+1.4%$23.37 billion$11.55 billion27.93
Quest Diagnostics logo
DGX
Quest Diagnostics
2.1$115.59+0.8%$15.43 billion$7.73 billion14.29Insider Selling
Guardant Health logo
GH
Guardant Health
1.7$147.18+1.5%$14.71 billion$214.38 million-77.06Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Natera logo
NTRA
Natera
1.5$116.09+6.3%$9.91 billion$302.33 million-48.78Earnings Announcement
Analyst Report
Insider Selling
News Coverage
CareDx logo
CDNA
CareDx
1.2$79.08+0.2%$3.90 billion$127.07 million-171.91Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Veracyte logo
VCYT
Veracyte
1.2$58.06+0.9%$3.89 billion$120.37 million-84.14Analyst Report
Decrease in Short Interest
Gap Down
BNR
Burning Rock Biotech
0.9$35.99+0.9%$3.66 billionN/A0.00
Fulgent Genetics logo
FLGT
Fulgent Genetics
1.2$101.26+1.5%$2.46 billion$32.53 million50.13Upcoming Earnings
Decrease in Short Interest
News Coverage
GTH
Genetron
0.4$24.59+6.4%$2.17 billion$45.68 million0.00Increase in Short Interest
Gap Down
Castle Biosciences logo
CSTL
Castle Biosciences
1.5$76.08+2.1%$1.53 billion$51.87 million-447.50Insider Selling
News Coverage
DermTech logo
DMTK
DermTech
1.5$66.73+6.6%$1.31 billion$3.36 million-39.49Upcoming Earnings
Decrease in Short Interest
Gap Down
Personalis logo
PSNL
Personalis
1.8$30.83+2.8%$1.20 billion$65.21 million-29.08Earnings Announcement
Analyst Report
News Coverage
RadNet logo
RDNT
RadNet
1.5$18.44+1.8%$952.17 million$1.15 billion-87.81
RNLX
Renalytix AI
0.9$22.80+2.2%$821.14 millionN/A-142.50Upcoming Earnings
Increase in Short Interest
Gap Down
Progenity logo
PROG
Progenity
2.2$5.47+1.8%$298.78 millionN/A0.00Upcoming Earnings
Exagen logo
XGN
Exagen
1.8$18.29+5.2%$231.41 million$40.39 million-1.49Gap Down
Centogene logo
CNTG
Centogene
1.2$11.56+3.9%$229.59 million$54.64 million-7.92News Coverage
Gap Down
CELC
Celcuity
1.4$14.20+2.7%$146.32 millionN/A-16.71
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.92+1.0%$139.85 million$76.02 million-6.79Upcoming Earnings
News Coverage
Biocept logo
BIOC
Biocept
1.2$6.03+3.5%$80.78 million$5.53 million-1.50Gap Down
ANPC
AnPac Bio-Medical Science
0.7$6.61+0.9%$74.04 million$1.56 million-4.08Increase in Short Interest
Miragen Therapeutics logo
MGEN
Miragen Therapeutics
0.9$16.44+3.3%$64.25 million$4.46 million-1.54Gap Down
OpGen logo
OPGN
OpGen
1.3$2.29+3.5%$51.50 million$3.50 million-1.13Analyst Upgrade
Decrease in Short Interest
Gap Down
PMD
Psychemedics
0.9$7.00+1.1%$38.69 million$37.68 million-10.14Upcoming Earnings
Increase in Short Interest
News Coverage
Cancer Genetics logo
CGIX
Cancer Genetics
0.6$6.51+1.4%$26.59 million$7.30 million-3.14Gap Up
AMS
American Shared Hospital Services
0.1$2.80+5.7%$16.13 million$20.60 million-28.00High Trading Volume
Gap Up
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.